Exploring the factors and barriers of healthcare professionals in tertiary care hospitals toward pharmacovigilance: a multicenter study from Khyber Pakhtunkhwa, Pakistan

References

• Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437–453.
   PubMed Web of Science ®Google Scholar
• UMC. WHO programme for international drug monitoring. Geneva: Uppsala Monitoring Centre; 2019.
   Google Scholar
• Chokshi A, Sifri Z, Cennimo D, et al. Global contributors to antibiotic resistance. J Glob Infect Dis. 2019;11(1):36–42.
   PubMed Web of Science ®Google Scholar
• Patsuree A, Krska J, Jarernsiripornkul N. Experiences relating to adverse drug reactions in the community: a cross-sectional survey among patients and the general public in Thailand. Expert Opin Drug Saf. 2016;15(3):287–295.
   PubMed Web of Science ®Google Scholar
• Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today. 2015;105(2):140–156.
   PubMedGoogle Scholar
• World Health Organization. Quality A, safety of medicines T. Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action. Geneva: World Health Organization; 2002.
   Google Scholar
• Elkalmi RM, Hassali MA, Ibrahim MIM, et al. Pharmacy students’ knowledge and perceptions about pharmacovigilance in Malaysian public universities. Am J Pharm Educ. 2011;75(5):96.
   PubMed Web of Science ®Google Scholar
• Oreagba IA, Ogunleye OJ, Olayemi SO. The knowledge, perceptions and practice of pharmacovigilance amongst community pharmacists in Lagos state, South West Nigeria. Pharmacoepidemiol Drug Saf. 2011;20(1):30–35.
   PubMed Web of Science ®Google Scholar
• Shanko H, Abdela J. Knowledge, attitudes, and practices of health care professionals toward adverse drug reaction reporting in Hiwot Fana specialized university hospital, Harar, Eastern Ethiopia: a cross-sectional study. Hosp Pharm. 2018;53(3):177–187.
   PubMed Web of Science ®Google Scholar
• Güner MD, Ekmekci PE. Healthcare professionals' pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. J Drug Assess. 2019;8(1):13–20.
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31.
   PubMed Web of Science ®Google Scholar
• Hussain R, Hassali MA, Hashmi F, et al. Qualitative exploration of knowledge, attitudes and practices of hospital pharmacists towards adverse drug reaction reporting system in Lahore. Pakistan. J Pharm Policy Pr. 2018;11:16.
   PubMedGoogle Scholar
• Biswas P. Pharmacovigilance in Asia. J Pharmacol Pharmacother. 2013;4(Suppl 1):S7–S19.
   PubMedGoogle Scholar
• Data for lower middle income, Pakistan|Data [Internet] [cited 2021 Aug 26]. Available from: https://data.worldbank.org/?locations=XN-PK
   Google Scholar
• GBD Healthcare Access and Quality Collaborators. Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the global burden of disease study 2016. Lancet. 2018;391(10136):2236–2271.
   PubMed Web of Science ®Google Scholar
• Nisa ZU, Zafar A, Sher F. Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the Capital of Pakistan. Saudi Pharm J. 2018;26(4):453–461.
   PubMed Web of Science ®Google Scholar
• Hussain R, Hassali MA, Hashmi F, et al. Exploring healthcare professionals’ knowledge, attitude, and practices towards pharmacovigilance: a cross-sectional survey. J Pharm Policy Pr. 2021;14(1):5.
   PubMedGoogle Scholar
• Abdel-Latif MM, Abdel-Wahab BA. Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, kingdom of Saudi Arabia. Saudi Pharm J. 2015;23(2):154–161.
   PubMed Web of Science ®Google Scholar
• Sample size calculator by Raosoft, Inc. [Internet] [cited 2019 Jul 21]. Available from: http://www.raosoft.com/samplesize.html
   Google Scholar
• Gupta P, Udupa A. Adverse drug reaction reporting and pharmacovigilance: knowledge, attitudes and perceptions amongst resident doctors. J Pharm Sci Res. 2011;3(2):1064.
   Google Scholar
• Awodele O, Akinyede A, Adeyemi OA, Awodele DF. Pharmacovigilance amongst doctors in private hospitals in Lagos west senatorial district, Nigeria. Int J Risk Amp Saf Med. 2011;23(4):217–226.
   PubMedGoogle Scholar
• Sharma R. Article details study of key stakeholders for their knowledge, attitude and practice on adverse drug reaction reporting in tertiary care hospitals in Jaipur, India. IJP. 2017;2(2):1–11.
   Google Scholar
• Sahu RK, Yadav R, Prasad P, et al. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. Springerplus. 2014;3:695.
   PubMedGoogle Scholar
• Abu Hammour K, El-Dahiyat F, Abu Farha R. Health care professionals knowledge and perception of pharmacovigilance in a tertiary care teaching hospital in Amman, Jordan. J Eval Clin Pract. 2017;23(3):608–613.
   PubMed Web of Science ®Google Scholar
• Alshammari TM, Alamri KK, Ghawa YA, et al. Knowledge and attitude of health-care professionals in hospitals towards pharmacovigilance in Saudi Arabia. Int J Clin Pharm. 2015;37(6):1104–1110.
   PubMed Web of Science ®Google Scholar
• Gupta SK, Nayak RP, Shivaranjani R, et al. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in South India. Perspect Clin Res. 2015;6(1):45–52.
   PubMedGoogle Scholar
• Hussain R, Hassali MA, Babar Z-U-D. Quantitative methods in pharmacy practice research. In: Babar Z-U-D, editor. Encyclopedia of pharmacy practice and clinical pharmacy. Oxford: Elsevier; 2019. p. 22–28.
   Google Scholar
• Department of Health Khyber-Pakhtunkhwa. Health Policy Khyber-Pakhtunkhwa [Internet]; 2018. Available from: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=http%3A%2F%2Fhealthkp.gov.pk%2Fpublic%2Fuploads%2Fdownloads-41.pdf&clen=532627&chunk=true
   Google Scholar
• Kassa Alemu B, Biru TT. Health care professionals’ knowledge, attitude, and practice towards adverse drug reaction reporting and associated factors at selected public hospitals in northeast Ethiopia: a cross-sectional study. BioMed Res Int. 2019;2019:1–11.
   Web of Science ®Google Scholar
• Salehi T, Seyedfatemi N, Mirzaee MS, et al. Nurses’ knowledge, attitudes, and practice in relation to pharmacovigilance and adverse drug reaction reporting: a systematic review. Biomed Res Int. 2021;2021:6630404.
   PubMed Web of Science ®Google Scholar
• Lemay J, Alsaleh FM, Al-Buresli L, et al. Reporting of adverse drug reactions in primary care settings in Kuwait: a comparative study of physicians and pharmacists. Med Princ Pract. 2018;27(1):30–38.
   PubMed Web of Science ®Google Scholar
• Hussain R, Hassali MA, Ur Rehman A, et al. A qualitative evaluation of adverse drug reaction reporting system in Pakistan: findings from the nurses’ perspective. Int J Env Res Public Health. 2020;17(9):3039.
   PubMed Web of Science ®Google Scholar
• Babar Z-U-D, Scahill SL, Akhlaq M, et al. A bibliometric review of pharmacy education literature in the context of low-to middle-income countries. Curr Pharm Teach Learn. 2013;5(3):218–232.
   Google Scholar
• DRAP. Pakistan National Pharmacovigilance Guidelines 1st ed [Internet]; 2019. Available from: https://efaidnbmnnnibpcajpcglclefindmkaj/viewer.html?pdfurl=https%3A%2F%2Fdra.gov.pk%2Fdocs%2FDraft%2520Pakistan%2520National%2520Pharmacovigigilance%2520guidlines%25204-9-2019.pdf&clen=3021294&chunk=true
   Google Scholar
• Shamim S, Sharib SM, Malhi SM, et al. Adverse drug reactions (ADRS) reporting: awareness and reasons of under-reporting among health care professionals, a challenge for pharmacists. Springerplus. 2016;5(1):1778.
   PubMedGoogle Scholar
• Palaian S, Ibrahim MI, Mishra P. Health professionals' knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharm Pract. 2011;9(4):228–235.
   PubMedGoogle Scholar
• AlShammari TM, Almoslem MJ. Knowledge, attitudes & practices of healthcare professionals in hospitals towards the reporting of adverse drug reactions in Saudi Arabia: a multi-Centre cross sectional study. Saudi Pharm J. 2018;26(7):925–931.
   PubMed Web of Science ®Google Scholar
• Hussain R, Hassali MA, Ur Rehman A, et al. Physicians’ understanding and practices of pharmacovigilance: qualitative experience from a lower Middle-Income country. Int J Env Res Public Health. 2020;17(7):2209.
   PubMed Web of Science ®Google Scholar
• Mulatu WN, Alemayehu W. Assessment of knowledge, attitude and practice of health professionals towards adverse drug reaction reporting and factors associated with reporting. J Pharmacovigil. 2014;2(4):1–7.
   Google Scholar
• Amrain M, Bečić F. Knowledge, perception, practices and barriers of healthcare professionals in Bosnia and Herzegovina towards adverse drug reaction reporting and pharmacovigilance. JHSCI. 2014;4(2):120–125.
   Google Scholar
• Roberts PI, Wolfson DJ, Booth TG. The role of pharmacists in adverse drug reaction reporting. Drug Saf. 1994;11(1):7–11.
   PubMed Web of Science ®Google Scholar
• Shekelle PG, Wachter RM, Pronovost PJ, et al. Making health care safer II: an updated critical analysis of the evidence for patient safety practices. Evid Rep Technol Assess. 2013;(211):1–945.
   PubMedGoogle Scholar
• Hadi MA, Neoh CF, Zin RM, Elrggal ME, et al. Pharmacovigilance: pharmacists' perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract. 2017;6:91–98.
   PubMed Web of Science ®Google Scholar
• Osemene KP, Ayeni MI, Afolabi MO. The role of community pharmacists in monitoring adverse drug reactions in Nigeria. J Pharm Health Serv Res. 2012;3(4):197–204.
   Google Scholar
• Calvert R. Clinical pharmacy–a hospital perspective. Br J Clin Pharmacol. 1999;47(3):231–238.
   PubMed Web of Science ®Google Scholar
• Schlienger RG, Lüscher TF, Haefeli WE, et al. Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci. 1999;21(3):110–115.
   PubMedGoogle Scholar